methyl 4-(2-nitrophenyl)-3-butenoate | 1256598-37-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 4-(2-nitrophenyl)-3-butenoate
• 英文别名: (E)-methyl 4-(2-nitrophenyl)but-3-enoate；methyl (E)-4-(2-nitrophenyl)but-3-enoate
• CAS: 1256598-37-4
• 化学式: C₁₁H₁₁NO₄
• 分子量: 221.213
• InChiKey: RBHFZPJXXYYPHP-GQCTYLIASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  72.1
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2-(2-硝基苯基)乙醛 在 甲氧羰基亚甲基三苯基正膦 作用下， 以 甲苯 为溶剂， 反应 3.0h， 生成 methyl 4-(2-nitrophenyl)-3-butenoate
  参考文献：
  名称：

  [EN] MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF
  [FR] MODULATEURS DES RÉCEPTEURS 5-HT, ET PROCÉDÉS D'UTILISATION CORRESPONDANTS

  摘要：

  本申请涉及式(I)的芳基和杂芳基融合的十氢吡咯环庚烷、八氢氧杂环己烯基吡咯、八氢吡咯噻环庚烷二氧化物、十氢环庚[c]吡咯和八氢环庚[c]吡咯衍生物，其中R1、R2、R3、R4、R5、A、Y1、Y2和Y3如规范中所定义。本申请还涉及包含这些化合物的组合物、制备这些化合物的方法，以及使用这些化合物和组合物治疗疾病症状的方法，以及鉴定这些化合物的方法。

  公开号：

  WO2010135560A1

文献信息

• MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF
  申请人：Akritopoulou-Zanze Irini

  公开号：US20110118231A1

  公开（公告）日：2011-05-19

  The present application relates to aryl- and heteroaryl-fused decahydropyrroloazepine, octahydrooxepinopyrrole, octahydropyrrolothiazepine dioxide, decahydrocyclohepta[c]pyrrole, and octahydrocyclohepta[c]pyrrole derivatives of formula (I) wherein R 1 , R 2 , R 3 , R 4 , R 5 , A, Y 1 , Y 2 , and Y 3 are as defined in the specification. The present application also relates to compositions comprising such compounds, processes for making such compounds, and methods of treating disease conditions using such compounds and compositions, and methods for identifying such compounds.

  本申请涉及公式（I）的芳基和杂环芳基融合的十氢吡咯-氮杂环庚烷、八氢氧杂环吡咯、八氢吡咯硫杂环庚烷二氧化物、十氢环庚烷[c]吡咯和八氢环庚烷[c]吡咯衍生物，其中R1、R2、R3、R4、R5、A、Y1、Y2和Y3如规范中所定义。本申请还涉及包含这些化合物的组合物、制备这些化合物的方法、使用这些化合物和组合物治疗疾病状况的方法，以及识别这些化合物的方法。
• Modulators of 5-HT receptors and methods of use thereof
  申请人：Akritopoulou-Zanze Irini

  公开号：US08846951B2

  公开（公告）日：2014-09-30

  The present application relates to aryl- and heteroaryl-fused decahydropyrroloazepine, octahydrooxepinopyrrole, octahydropyrrolothiazepine dioxide, decahydrocyclohepta[c]pyrrole, and octahydrocyclohepta[c]pyrrole derivatives of formula (I) wherein R1, R2, R3, R4, R5, A, Y1, Y2, and Y3 are as defined in the specification. The present application also relates to compositions comprising such compounds, processes for making such compounds, and methods of treating disease conditions using such compounds and compositions, and methods for identifying such compounds.

  本申请涉及公式（I）的芳基和杂环芳基融合的十氢吡咯环己烷、八氢氧杂环戊烷基吡咯、八氢吡咯硫环己烷二氧化物、十氢环庚[c]吡咯和八氢环庚[c]吡咯衍生物，其中R1、R2、R3、R4、R5、A、Y1、Y2和Y3如规范中所定义。本申请还涉及包含这样的化合物的组合物，制备这样的化合物的方法，使用这样的化合物和组合物治疗疾病状况的方法，以及识别这样的化合物的方法。
• Process for preparing urokinase complex
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：EP0109653A2

  公开（公告）日：1984-05-30

  This invention provides a process for preparing a fibrin-adsorable protein-urokinase complex characterized by reacting a protein adsorbable by fibrin with urokinase in the presence of a protein coupling reagent represented by the formula wherein R is phenylene or cycloalkylene, A is lower alkylene, B is lower alkylene which may optionally be substituted by lower alkylthio or phenyl-lower alkylthio, and ℓ, m and n are each 0 or 1 provided that ℓ, m and n are not 0 at the same time. The complex is useful as a thrombolytic agent.

  本发明提供了一种制备纤维蛋白-可吸附蛋白质-尿激酶复合物的工艺，其特征在于在由式 所表示的蛋白质偶联试剂存在下，使可被纤维蛋白吸附的蛋白质与尿激酶反应。 其中 R 是亚苯基或环烷基，A 是低级亚烷基，B 是可被低级烷硫基或苯基-低级烷硫基取代的低级亚烷基，ℓ、m 和 n 各为 0 或 1，但 ℓ、m 和 n 不能同时为 0。 该复合物可用作血栓溶解剂。
• Preparation of modulators of 5-HT receptors
  申请人：AbbVie Inc.

  公开号：EP2641907A1

  公开（公告）日：2013-09-25

  The present application relates to processes for making aryl- and heteroaryl-fused decahydropyrroloazepine derivatives of formula (1-5), wherein the variables are as defined in the specification.

  本申请涉及式（1-5）芳基和杂芳基融合的十氢吡咯并氮杂卓衍生物的制造工艺，其中变量如说明书中所定义。
• 3-Cyano-Quinoline Derivatives With Antiproliferative Activity
  申请人：Freyne Eddy Jean Edgard

  公开号：US20080139601A1

  公开（公告）日：2008-06-12

  The present invention concerns the compounds of formula the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein Z represents NH; Y represents —C 3-9 alkyl-, —C 1-5 alkyl-NR 12 —C 1-5 alkyl-, —C 1-6 alkyl-NH—CO— or —CO—NH—C 1-6 alkyl-; X 1 represents —O—; X 2 represents a direct bond, —NR 11 —C 1-2 alkyl-, —NR 11 —CH 2 —, —C 1-2 alkyl-, —O—C 1-2 alkyl, —O— or —O—CH 2 —; R 1 represents hydrogen or halo; R 2 represents hydrogen, cyano, halo, hydroxycarbonyl-, C 1-4 alkyloxycarbonyl-, Het 16 -carbonyl- or Ar 5 ; R 3 represents hydrogen, hydroxy, C 1-4 alkyloxy-, Ar 4 —C 1-4 alkyloxy or R 3 represents C 1-4 alkyloxy substituted with one or where possible two or more substituents selected from C 1-4 alkyloxy- or Het 2 -; R 10 represents hydrogen; R 11 represents hydrogen, C 1-4 alkyl- or C 1-4 alkyl-oxy-carbonyl-; R 12 represents Het 14 -C 1-4 alkyl, in particular morpholinyl-C 1-4 alkyl; Het 2 represents a heterocycle selected from morpholinyl or piperidinyl optionally substituted with C 1-4 alkyl-, preferably methyl; Het 14 represents morpholinyl; Het 16 represents a heterocycle selected from morpholinyl or pyrrolidinyl; Ar 4 represents phenyl; Ar 5 represents phenyl optionally substituted with cyano.